<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="812">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150587</url>
  </required_header>
  <id_info>
    <org_study_id>RE-ROS2002-2021</org_study_id>
    <nct_id>NCT05150587</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea</brief_title>
  <official_title>A Phase IIa, Multicenter, Double Blind, Placebo Controlled, Randomized Clinical Trial to Assess Safety, Efficacy and Pharmacokinetics of Rifaximin Delayed-Release (Rifaximin-EIR) in Patients With Moderate-to-severe Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfasigma S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bioRASI, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alfasigma S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost&#xD;
      exclusively affecting the central area of the face and the eyes.&#xD;
&#xD;
      Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral&#xD;
      antibiotic drug may be beneficial in patients with rosacea, particularly in those with&#xD;
      papulopustular phenotype and positivity to Lactulose Breath Test (L-BT).&#xD;
&#xD;
      The objective of this study is twofold:&#xD;
&#xD;
        1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults&#xD;
           with moderate-to-severe papulopustular rosacea.&#xD;
&#xD;
        2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of&#xD;
           patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Number of rosacea inflammatory lesions</measure>
    <time_frame>30 days</time_frame>
    <description>Change from baseline in number of rosacea inflammatory lesions (papules and pustules) at the end of treatment.&#xD;
This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints will be satisfied (note: the two items may not necessarily occur in the same patient).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of subjects showing treatment success at the end of treatment. This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints will be satisfied (note: the two items may not necessarily occur in the same patient).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Rifaximin-Tested dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin-Tested dose B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin tablets</description>
    <arm_group_label>Rifaximin-Tested dose A</arm_group_label>
    <arm_group_label>Rifaximin-Tested dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 years or older at screening (V1)&#xD;
&#xD;
          -  Female participants are eligible if they are: i) of non-childbearing potential or ii)&#xD;
             of childbearing potential with a negative pregnancy test result at screening and&#xD;
             randomization AND agreeing to use a highly effective method of contraception until 72&#xD;
             hours after taking the last study treatment dose.&#xD;
&#xD;
          -  Presence of rosacea, papulopustular phenotype.&#xD;
&#xD;
          -  Moderate or severe rosacea based on Investigator's Global Assessment based on&#xD;
             Investigator's judgement.&#xD;
&#xD;
          -  Patients accepting to provide and legally capable of providing free and informed&#xD;
             consent to all procedures included in the protocol (including the availability to&#xD;
             perform a Lactulose Breath Test).&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Granulomatous rosacea or rosacea fulminans.&#xD;
&#xD;
          -  Hypersensitivity or intolerance to lactulose or any excipient of the lactulose&#xD;
             preparation to be used for L-BT.&#xD;
&#xD;
          -  History of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other&#xD;
             conditions characterized by severe intestinal ulcers.&#xD;
&#xD;
          -  Patients with intestinal obstruction or partial intestinal obstruction.&#xD;
&#xD;
          -  Severe kidney impairment (i.e. estimated glomerular filtration rate &lt;30 ml/min).&#xD;
&#xD;
          -  Severe hepatic impairment (i.e. Child-Pugh B or C).&#xD;
&#xD;
          -  Cancer or any cancer-related treatment within 5 years prior to screening (excluding&#xD;
             non-melanoma skin-cancer).&#xD;
&#xD;
          -  History of alcohol or drug abuse within a year prior to screening, based on&#xD;
             Investigator's judgement.&#xD;
&#xD;
          -  Facial skin conditions that can interfere with reliable assessment of rosacea&#xD;
             throughout the study (e.g. facial hair, tattoos, other facial adornments, keloids,&#xD;
             hypertrophic scarring, recent facial surgery, excessive sun exposure including use of&#xD;
             tanning beds)&#xD;
&#xD;
          -  Any other significant health condition (e.g. cardiovascular, respiratory, renal,&#xD;
             hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) or non-health&#xD;
             condition that in the investigator's judgement may: i) jeopardize the patient's safe&#xD;
             participation in the trial or ii) make unlikely the patient's completion of the study&#xD;
             or iii) make unlikely the patient's compliance with the study procedures (e.g. highly&#xD;
             anticipated need of non-permitted treatments, terminal illness, etc.).&#xD;
&#xD;
          -  History of hypersensitivity to the study drug.&#xD;
&#xD;
          -  Treatment with biologic immunomodulatory and/or immunosuppressive drugs (e.g. anti-TNF&#xD;
             drugs) within 6 months prior to randomization.&#xD;
&#xD;
          -  Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g.&#xD;
             cyclosporine, methotrexate etc.) within 30 days prior to randomization.&#xD;
&#xD;
          -  Treatment with warfarin (or other coumarins) within 14 days prior to randomization.&#xD;
&#xD;
          -  Treatment with niacin within 30 days prior to randomization.&#xD;
&#xD;
          -  Topical facial or systemic antibiotics within 30 days before randomization;&#xD;
&#xD;
          -  Treatment with neomycin or other low-absorbable oral antibiotics within 90 days before&#xD;
             randomization.&#xD;
&#xD;
          -  Topical facial, inhaled or systemic corticosteroids within 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Topical facial retinoids within 30 days before randomization.&#xD;
&#xD;
          -  Systemic retinoids within 6 months before randomization.&#xD;
&#xD;
          -  Any other topical or systemic treatment for rosacea within 30 days before&#xD;
             randomization (including also laser and pulsed light, etc.).&#xD;
&#xD;
          -  Over-the-counter intestinal or topical skin probiotics (functional food is allowed),&#xD;
             within 30 days before randomization.&#xD;
&#xD;
          -  Any experimental treatment within 6 months prior to randomization.&#xD;
&#xD;
          -  Current swab-positive or suspected (under investigation) Covid-19 infection; or fever&#xD;
             and one or more of the following respiratory disease signs or symptoms: cough, sputum&#xD;
             production, shortness of breath within the last 14 days; or contact with people with&#xD;
             Covid-19 infection within the last 14 days.&#xD;
&#xD;
          -  Women who are pregnant, breast-feeding or planning a pregnancy during the trial&#xD;
             period.&#xD;
&#xD;
          -  Subjects who are investigational site staff members and their family members, site&#xD;
             staff members otherwise supervised by the investigator, or patients who are&#xD;
             Alfasigma's employees.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth M Scheidt</last_name>
    <phone>1-800-867-9150</phone>
    <email>escheidt@biorasi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services, PLLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Co, Inc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>December 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 8, 2021</last_update_submitted>
  <last_update_submitted_qc>December 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

